Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF2R | P11717 | 5/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26359469 | 0.91 | IGF2R (0.36) | IGF2RCA1CA2CA9 | |
| SCHEMBL26359482 | 0.89 | LGALS8 (0.40) | IGF2RLGALS8 | |
| SCHEMBL26359489 | 0.88 | IGF2R (0.40) | IGF2RLGALS8 | |
| SCHEMBL26359458 | 0.84 | IGF2R (0.43) | IGF2RLGALS8 | |
| SCHEMBL26359486 | 0.81 | MAPK1 (0.50) | LGALS8CA1CA2CA9 | |
| SCHEMBL26359464 | 0.81 | IGF2R (0.38) | IGF2R | |
| SCHEMBL26031867 | 0.79 | IGF2R (0.36) | IGF2RLGALS8CA1CA2CA9 | |
| SCHEMBL26359481 | 0.79 | LGALS8 (0.42) | IGF2RLGALS8 | |
| SCHEMBL26359450 | 0.79 | IGF2R (0.41) | IGF2RCA1CA2CA9 | |
| SCHEMBL24724844 | 0.78 | LMNA (0.42) | IGF2RLGALS8CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | IGF2R 833/4885LGALS8 968/4885CA1 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.